Premium
The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea
Author(s) -
Nam J. S.,
Kim A. R.,
Yoon J. C.,
Byun Y.,
Kim S. A.,
Kim K. R.,
Cho S.,
Seong B. L.,
Ahn C. W.,
Lee J. M.
Publication year - 2011
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03255.x
Subject(s) - medicine , seroconversion , antibody , diabetes mellitus , vaccination , immunology , trivalent influenza vaccine , type 1 diabetes , influenza a virus , influenza vaccine , virus , endocrinology
Diabet. Med. 28, 815–817 (2011) Abstract Aims We evaluated the antibody response to a single‐dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses. Methods Eighty‐two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti‐haemagglutinin antibody ELISA. Results Among 70 antibody‐negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1‐specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate. Conclusions Our data show low cross‐reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger‐scale, case‐controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two‐dose vaccination or have antibody titres measured after the first vaccination.